Kubota Pharmaceutical Holdings Past Earnings Performance
Past criteria checks 0/6
Kubota Pharmaceutical Holdings has been growing earnings at an average annual rate of 6.9%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 22.3% per year.
Key information
6.9%
Earnings growth rate
11.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 22.3% |
| Return on equity | -51.0% |
| Net Margin | -24,423.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kubota Pharmaceutical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 8 | -2,016 | 601 | 0 |
| 30 Sep 22 | 2 | -2,366 | 558 | 1,845 |
| 30 Jun 22 | 0 | -2,462 | 529 | 1,952 |
| 31 Mar 22 | 0 | -2,575 | 571 | 2,032 |
| 31 Dec 21 | 0 | -2,616 | 604 | 2,040 |
| 30 Sep 21 | 0 | -2,496 | 606 | 1,943 |
| 30 Jun 21 | 0 | -2,534 | 635 | 1,949 |
| 31 Mar 21 | 37 | -2,420 | 626 | 1,898 |
| 31 Dec 20 | 37 | -2,437 | 607 | 1,972 |
| 30 Sep 20 | 37 | -2,679 | 603 | 2,275 |
| 30 Jun 20 | 37 | -2,896 | 592 | 2,496 |
| 31 Mar 20 | 0 | -3,083 | 567 | 2,712 |
| 31 Dec 19 | 0 | -3,065 | 532 | 2,756 |
| 30 Sep 19 | 0 | -3,121 | 611 | 2,729 |
| 30 Jun 19 | 0 | -3,084 | 660 | 2,655 |
| 31 Mar 19 | 0 | -3,045 | 718 | 2,554 |
| 31 Dec 18 | 0 | -3,046 | 794 | 2,479 |
| 30 Sep 18 | 0 | -2,832 | 794 | 2,244 |
| 30 Jun 18 | 0 | -2,842 | 878 | 2,602 |
| 31 Mar 18 | 0 | -3,102 | 1,028 | 2,058 |
| 31 Dec 17 | 0 | -3,444 | 1,240 | 2,379 |
| 30 Sep 17 | 39 | -3,516 | 1,503 | 1,868 |
| 30 Jun 17 | 109 | -3,472 | 1,642 | 1,213 |
| 31 Mar 17 | 415 | -3,349 | 2,003 | 1,205 |
| 31 Dec 16 | 889 | -4,035 | 2,290 | 1,066 |
| 30 Sep 16 | 1,075 | -4,004 | 861 | 1,093 |
| 30 Jun 16 | 1,738 | -3,607 | 694 | 766 |
| 31 Mar 16 | 2,327 | -3,963 | 1,211 | 812 |
Quality Earnings: KBBT.F is currently unprofitable.
Growing Profit Margin: KBBT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KBBT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare KBBT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KBBT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: KBBT.F has a negative Return on Equity (-51.04%), as it is currently unprofitable.